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Abstract 
Background: The industrial use of enzymes produced by microorganisms is continuously growing due to the need 
for sustainable solutions. Nevertheless, many of the plasmids used for recombinant production of proteins in bacteria 
are based on the use of antibiotic resistance genes as selection markers. The safety concerns and legal requirements 
surrounding the increased use of antibiotic resistance genes have made the development of new antibiotic-free 
approaches essential.
Results: In this work, a system completely free of antibiotic resistance genes and useful for the production of high 
yields of proteins in Streptomyces is described. This system is based on the separation of the two components of the 
yefM/yoeBsl (antitoxin/toxin) operon; the toxin (yoeBsl) gene, responsible for host death, is integrated into the genome 
and the antitoxin gene (yefMsl), which inactivates the toxin, is located in the expression plasmid. To develop this 
system, the toxin gene was integrated into the genome of a strain lacking the complete operon, and the antibiotic 
resistance gene integrated along with the toxin was eliminated by Cre recombinase to generate a final host strain free 
of any antibiotic resistance marker. In the same way, the antibiotic resistance gene from the final expression plasmid 
was removed by Dre recombinase. The usefulness of this system was analysed by checking the production of two 
hydrolases from different Streptomyces. Production of both proteins, with potential industrial use, was high and stable 
over time after strain storage and after serial subcultures. These results support the robustness and stability of the 
positive selection system developed.
Conclusions: The total absence of antibiotic resistance genes makes this system a powerful tool for using Streptomy-
ces as a host to produce proteins at the industrial level. This work is the first Streptomyces antibiotic marker-free system 
to be described.
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Background
The use of living organisms to produce commercially 
important value-added biomolecules is of great impor-
tance for the different industrial sectors of society such as 
agriculture, food, energy and pharmaceutical. Recently, 
Zhang et  al. classified the use of organisms, called 
biomanufacturing, into four historical revolutions. Het-
erologous protein production, also called biologics [1], 
corresponds to what is known as biomanufacturing 3.0. 
This type of technology began in the 1980s with the pro-
duction of large-size proteins like erythropoietin, insulin, 
among others, from genetically modified microorganisms 
[2] thanks to the development of recombinant DNA and 
advanced cell culture techniques.
Many of the proteins produced by this DNA recom-
binant technology are hydrolytic enzymes like amyl-
ases, cellulases, hemicellulases, lipases and proteases, 
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which are important products for many different types of 
industries such as food and beverages, textile, detergent, 
pharmaceuticals [3], animal feed [4], biofuels and fine-
chemical industries, among others. Presently, approxi-
mately 90% of industrial enzymes are recombinant 
versions produced in bacteria and fungi [5], and their use 
is expected to increase due to a growing need for sustain-
able solutions. Moreover, the discovery of new enzymes 
to add to the currently available toolbox and the develop-
ment of optimized strategies for the production of these 
hydrolytic enzymes is a central goal of many industrial 
sectors [6].
There is a wide spectrum of hosts used as expression 
systems for the production of recombinant proteins 
that include bacteria, yeast, filamentous fungi, insect 
and mammalian cells and whole transgenic plants and 
animals [7]. Although the use of each host has different 
advantages and disadvantages, their main objective is 
process optimisation [7]. The most commonly used host 
to produce recombinant proteins is E. coli owing to its 
easy and rapid growth. However, the use of E. coli does 
present several drawbacks which can be overcome by 
the use of other types of host. Gram-positive hosts, such 
as Streptomyces, are an excellent alternative due to high 
secretion efficiency, which makes their use feasible for 
the direct release of proteins of interest into the culture 
medium. This in turn facilitates downstream procedures, 
such as extraction and purification, and consequently 
decreases the costs associated with the production of 
recombinant proteins. In addition, some Streptomyces 
strains have a relatively low level of endogenous extracel-
lular proteolytic activity in comparison with other hosts 
[8, 9]. Also, Streptomyces has proved useful to produce 
high levels of different proteins [8–12].
The use of enzymes produced by microorganisms as 
biocatalysts in industry can be considered “green chem-
istry” because no toxic waste is generated [6]. Never-
theless, many of the plasmids used for recombinant 
production of enzymes are based on the use of antibiotic 
resistance genes as selection markers. Due to the inten-
sifying problem of the appearance of antibiotic resist-
ant strains [13–15] and more legal requirements, it is 
important to avoid the use of these antibiotics as much 
as possible in the industrial process. As regards different 
antibiotic-free approaches have been developed, which 
include the complementation of auxotrophic bacterial 
strains, toxin-antitoxin-based systems, operator-repres-
sor titration, RNA-based selection markers and the over-
expression of essential genes. These alternative selection 
systems are summarized in Vandermeulen et al. [16].
Toxin-antitoxin systems (TAs) are ubiquitous in plas-
mids and genomes of bacteria and archaea, and are 
small genetic modules composed of a biologically active 
protein molecule (toxin) and the corresponding inhibitor 
(antitoxin). Many functions have been assigned to TAs 
like DNA stabilization, stress response, persistence and 
protection against mobile genetic elements [17–20]. The 
efficiency of these TAs depends on the different stability 
of both components, where toxins are highly resistant 
to proteases and antitoxins are more labile and readily 
degraded by proteases.
In view of this, our group developed a separate compo-
nent stabilization (SCS) system for Streptomyces lividans 
based on the yefM/yoeBsl toxin-antitoxin operon [21]. In 
this system the toxin (yoeBsl) gene, responsible for host 
death, is integrated into the genome, and the antitoxin 
(yefMsl) gene which inactivates the toxin is located in 
the expression plasmid [22]. To develop this system, the 
toxin (yoeBsl) gene was integrated into the genome of a 
strain lacking the complete operon, and with the anti-
toxin (yefMsl) gene carried by a thermosensitive plasmid 
[strain: S. lividans ∆TA (pGM160-YefMslts)] [22]. This 
strain was the starting point for the improvement of the 
Streptomyces SCS expression system, as described in the 
Results section. After toxin integration, the expression 
plasmids with the gene(s) of interest and the antitoxin are 
introduced into the host strain [S. lividans ∆TA-pKC796-
Tox (pGM160-YefMslts)] in place of the thermosensitive 
plasmid, and ultimately used for heterologous protein 
production. Thus, the antitoxin counteracts the effect of 
the toxin when the expression plasmid is present in the 
cell. By contrast, when the plasmid is lost the toxin causes 
cell death, ensuring that only the plasmid-containing 
cells persist [22]. Using this system, stable and high pro-
teins yields, without the addition of antibiotics into the 
production process, was achieved [22]. This SCS strategy 
has also been shown to be effective in E. coli [23–26].
Additionally, it must be noted that although this SCS 
system does not require the addition of antibiotics to 
maintain the stable production of enzymes of interest, 
the antibiotic markers are still present in the host strain 
and in the expression plasmids used. These antibiotic 
resistance genes comprise a potential risk for antibi-
otic resistance transmission by horizontal gene transfer 
[27–29].
In this work, we developed an optimized version of the 
S. lividans SCS expression platform previously reported 
[22]. Both, the apramycin resistance gene from the host 
strain and the neomycin resistance gene from the expres-
sion plasmids have been removed to obtain a completely 
antibiotic marker-free system. To this end, two site-
specific recombinases (SSRs) Cre and Dre were used to 
construct the host strain and the expression plasmids. 
Although SSR methodology has been applied in actino-
mycete genome manipulation for more than 20  years 
[30], it is only recently that the use of new SSRs has 
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been optimized in these microorganisms, broadening 
their possible application [30–33]. The strategy followed 
within this work is summarized in Fig. 1.
With this antibiotic marker-free system, the produc-
tion of two proteins, the α-amylase Amy from S. griseus 
IMRU3570 [34] and the xylanase Xys1 from S. halstedii 
JM8 [35], was high and stable over time, validating the 
efficiency of this new platform for heterologous produc-
tion of proteins in S. lividans. To our knowledge this is 
the first complete antibiotic marker-free system devel-
oped for Streptomyces. Thus, the total absence of antibi-
otic resistance genes presents an interesting potential use 
of this system in industry.
Results and discussion
Construction of an antibiotic marker‑free host strain
As mentioned above, in a previous work, the strain S. liv-
idans ∆TA-pKC796-Tox (pGM160-YefMslts) was used as 
a host to produce high levels of proteins without the use 
of antibiotics during the production step [22]. However, 
to obtain a completely antibiotic marker-free system it is 
necessary to delete the apramycin gene integrated into 
the genome during the generation of the strain. With 
this purpose in mind, a new plasmid pTES-Tox (Fig.  2a 
and Table 2) was used to integrate the toxin gene (yoeBsl) 
into the genome of the strain S. lividans ∆TA (pGM160-
YefMslts) [22]. In this new plasmid the toxin gene and 
the phage attachment site (attP) are flanked by the target 
sites for the Cre recombinase (loxP) (Fig. 2a).
Streptomyces lividans ΔTA (pGM160-YefMslts) strain 
[22], which harbours the temperature sensitive plasmid 
pGM160-YefMslts with the antitoxin gene (yefMsl) [22], 
was transformed with pTES-Tox generating the strain 
S. lividans ∆TA-pTES-Tox (pGM160-YefMslts) (step 
1 in Fig.  1). Then, this strain was transformed with the 
plasmid  pALCrets [33] encoding the Cre recombinase 
yielding S. lividans ∆TA-pTES-Tox (pGM160-YefMslts, 
 pALCrets) strain (step 2 in Fig. 1). Afterwards, the induc-
tion of this Cre recombinase allowed the plasmid back-
bone between the two loxP sites to be deleted, leaving 
only the toxin gene integrated in the genome (Fig.  2b). 
Successful elimination of the apramycin resistance gene 
was checked by PCR (Fig. 2c). The strain obtained after 
the elimination of apramycin gene was designated S. liv-
idans ∆TA-Tox (pGM160-YefMslts,  pALCrets) (step 3 in 
Fig.  1) and was used as the final antibiotic marker-free 
host to produce heterologous proteins in S. lividans.
Effectiveness of the antibiotic marker‑free host strain 
to produce high levels of protein
The usefulness of this new strain S. lividans ∆TA-Tox 
(pGM160-YefMslts,  pALCrets), without apramycin 
resistance in its genome, was analysed by checking the 
production of two proteins: the Amy α-amylase from 
S. griseus IMRU3570 [34] and the Xys1 xylanase from 
S. halstedii JM8 [35]. S. lividans wt and S. lividans ∆TA 
strains were used as controls.
Two new expression plasmids pNRoxAnti-Amy and 
pNRoxAnti-Xyl were generated (Fig.  3a, c). These plas-
mids harbour the antitoxin (yefMsl) gene under the con-
trol of the xylanase promoter xysAp [35] and the Amy 
α-amylase or the Xys1 xylanase, respectively, under the 
control of pstSp promoter from S. lividans [36]. These 
plasmids were generated with the target sites for the Dre 
recombinase (rox) flanking the neomycin resistance gene 
for its subsequent elimination (see below). In general, the 
expression plasmid generated was named pNRoxAnti-
Prot (Fig. 1).
Streptomyces lividans ∆TA-Tox (pGM160-YefMslts, 
 pALCrets) and the control strains (S. lividans wt and S. 
lividans ∆TA) were transformed with pNRoxAnti-Amy 
or pNRoxAnti-Xyl (step 4 in Fig. 1). After removal of the 
temperature sensitive plasmids (pGM160-YefMslts and 
 pALCrets) by incubation at 37 °C, the transformants were 
cultured at 28  °C in liquid YES medium without antibi-
otic and supplemented with 3% xylose to induce both 
promoters. The production of amylase or xylanase was 
analysed by SDS-PAGE of the supernatants collected 
after 6 days of culture (Fig. 3b, d).
A high production of amylase or xylanase was observed 
with the S. lividans ∆TA-Tox strain; however, no amyl-
ase and xylanase production was observed in the control 
strains (S. lividans wt and S. lividans ∆TA) (Fig.  3b, d). 
These results indicate that the toxin gene in the genome 
of the S. lividans ∆TA-Tox strain was exerting a positive 
selection for the maintenance of the expression plasmids 
containing the antitoxin, since the loss of the latter results 
in cell death. In contrast, in absence of antibiotic selec-
tion pressure, the expression plasmids (pNRoxAnti-Amy 
or pNRoxAnti-Xyl) present in the control strains (S. liv-
idans wt and S. lividans ∆TA) were lost and consequently 
no protein production was observed (Fig. 3b, d).
Therefore, the new strain (S. lividans ∆TA-Tox) without 
apramycin resistance allowed positive plasmid selection 
in the same way as the previously reported (S. lividans 
∆TA-pKC796-Tox) [22] but without the potential prob-
lems associated with the remaining presence of an antibi-
otic resistance gene in the host strain.
Elimination of the antibiotic marker gene in the expression 
plasmid and analysis of protein production
Nevertheless, it is still necessary to eliminate the neomy-
cin resistance gene present in the expression plasmids 
used (pNRoxAnti-Amy or pNRoxAnti-Xyl) in order to 
generate a completely antibiotic marker-free system. 
This antibiotic resistance gene was necessary to make the 
Page 4 of 13Sevillano et al. Microb Cell Fact  (2017) 16:164 
S. lividans ∆TA-Tox
(pRoxAnti-Prot)
SC
AR
Expression 
vector
1 pTES-Tox
S. lividans ∆TA-pTES-Tox
(pGM160-YefMslts)
SC
AR
pGM160-
YefMslts
S. lividans ∆TA-Tox
(pGM160-YefMslts, pALCrets)
SC
AR
pALCretspGM160-
YefMslts
SC
AR
S. lividans ∆TA
(pGM160-YefMslts)
pGM160-
YefMslts
S. lividans ∆TA-Tox
(pRoxAnti-Prot, pALDrets)
SC
AR
Expression 
vector
pALDrets
6pALDrets
YefMsl gene (antitoxin)
YoeBsl gene (toxin)
TS pGM160-YefMslts
Gene encoding the protein of interest
pNRoxAnti-Prot (Expression vector)Expression vector
Cre gene
Apra
Dre gene
pALCretsTS
pALDretsTS
pTES-Tox
S. lividans ∆TA-pTES-Tox
(pGM160-YefMslts, pALCrets)
SC
AR
pGM160-
YefMslts
pALCrets
3
SC
AR
S. lividans ∆TA-Tox S. lividans ∆TA-Tox
(pNRoxAnti-Prot)
SC
AR
Expression 
vector
4
Expression 
vector
pGM160-
YefMslts
pALCrets
4
7
SDS-PAGE
2 pALCrets
5 pALDrets
Fig. 1 Diagram of the separate component-stabilization system in Streptomyces. 1. Integration of the toxin (yoeBsl) gene into the chromosome of 
the S. lividans ∆TA (pGM160-YefMslts) strain [22] with plasmid pTES-Tox. 2. Transformation with  pALCrets to generate S. lividans ∆TA-pTES-Tox (pGM160-
YefMslts,  pALCrets). 3. Elimination of apramycin resistance gene by induction of Cre recombinase. 4. Transformation with the expression plasmid 
(pNRoxAnti-Prot) and removal of the temperature-sensitive plasmids. 5. Transformation with  pALDrets and elimination of the neomycin resistance 
gene from the expression plasmid (pNRoxAnti-Prot) by Dre recombinase induction. 6. Removal of the temperature-sensitive plasmid  pALDrets and 
generation of the final host strain [S. lividans ∆TA -Tox (pRoxAnti-Prot)]. 7. Protein production
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constructions in E. coli but was subsequently eliminated 
in Streptomyces. To facilitate the deletion of the antibiotic 
marker gene, the target sites for Dre recombinase (rox) 
[33] were introduced flanking the neomycin resistance 
gene as mentioned before.
The transformation of the strains S. lividans ∆TA-Tox 
(pNRoxAnti-Amy) and S. lividans ∆TA-Tox (pNRoxAnti-
Xyl) with the plasmid  pALDrets [33] (step 5 in Fig.  1) 
resulted in the deletion, by Dre recombinase, of the 
neomycin gene flanked by the rox sites generating the 
plasmids pRoxAnti-Amy or pRoxAnti-Xyl. This plasmid 
lacking the neomycin resistance gene was called pRox-
Anti-Prot (Fig. 4a).
In order to check the effective deletion of the neomy-
cin resistance gene, after the elimination of the  pALDrets 
plasmid (step 6 in Fig.  1), the plasmids pRoxAnti-Amy 
and pRoxAnti-Xyl were recovered from the correspond-
ing S. lividans ∆TA-Tox strains and the elimination of the 
neomycin gene was confirmed by PCR and by restriction 
analysis (Fig. 4b, c).
The amount of protein produced after the elimination 
of the marker gene was analysed and compared to that 
produced with the parental plasmids harbouring the neo-
mycin resistance gene. Transformants of S. lividans ∆TA-
Tox (pRoxAnti-Amy) or ∆TA-Tox (pRoxAnti-Xyl) and 
transformants of S. lividans ∆TA-Tox (pNRoxAnti-Amy) 
or ∆TA-Tox (pNRoxAnti-Xyl) were cultured for 6 days at 
28 °C in liquid YES medium without antibiotic, and sup-
plemented with 3% xylose. The production of amylase or 
xylanase was analysed by SDS-PAGE using the collected 
supernatants (Fig.  4d, e). The amount of amylase and 
xylanase produced after the elimination of the neomycin 
resistance gene was similar to that obtained with the neo-
mycin resistant plasmids (Fig. 4d, e).
At the end of this process, a new expression platform 
for Streptomyces completely free of antibiotic resistance 
genes was developed and suitable to produce proteins at 
industrial level.
Plasmid stability
A robust system for producing proteins at the industrial 
level must have a high protein yield and also be able to 
maintain stable production. Stability of the developed 
antibiotic marker-free platform was analysed under 
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Fig. 2 Elimination of the apramycin resistance gene in the host strain genome. a Diagram of the integrative pTES-Tox plasmid. b Diagram of the 
pTES-Tox plasmid backbone deletion by the action of Cre recombinase (modified from [33]). c PCR amplification of the toxin gene (Tox) with prim-
ers LS-008 and LS-009 (1) and the apramycin resistance gene (Apra) with primers LS-113 and LS-114 (2) from S. lividans genomic DNA before, S. 
lividans ∆TA-pTES-Tox (−), and after, S. lividans ∆TA-Tox (+), Cre activity
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different conditions such as long-term culturing, after the 
strains were stored as frozen mycelia or as frozen spores 
and after serial subcultures.
Initially, plasmid stability in long-term cultures was 
analyzed by measuring the enzymatic activity in the 
supernatants of S. lividans ∆TA-Tox (pRoxAnti-Amy) 
and S. lividans ∆TA-Tox (pRoxAnti-Xyl) at different cul-
ture times (Fig.  5). An increase in enzyme production 
and activity were observed during the time of culture. 
After 8 days, high enzyme production was observed, sug-
gesting that the cells still contained the plasmids. The 
processing of both proteins over time was also observed 
(Fig. 5), as has been previously described [34, 37].
Streptomyces strains can be stored for long periods of 
time by freezing mycelia or spores in 20% glycerol. To 
check plasmid stability after mycelia freezing, 100 µL of 
frozen mycelia suspension, were inoculated into 10 mL 
of YES medium with 3% of xylose for 2  days. Then, 
100  µL of the preculture were reinoculated in 10  mL 
of YES medium with 3% of xylose for 6  days at 28  °C. 
Amylase and xylanase activities in the supernatants 
were compared with the activities observed in the origi-
nal cultures (Fig. 6b, d). Plasmid stability after sporula-
tion was analyzed in a similar way, 5 × 105 spores were 
inoculated in 10 mL of YES medium with 3% xylose for 
6  days and enzyme production was analyzed by SDS-
PAGE and by measuring enzymatic activity (Fig. 6b, d). 
More than 75% of enzymatic activity was obtained after 
the storage of the strains with two different methods. In 
the case of xylanase, the activity observed after freezing 
the mycelia was even greater than the original culture 
(Fig.  6d). These results again confirm the strong effi-
ciency of our system to stably maintain the expression 
plasmids.
Finally, plasmid stability was assessed after three serial 
100-fold dilutions (P1, P2 and P3) of cultures in fresh YES 
medium every 2 days. Using the same procedure as men-
tioned above, the amount of enzyme in the supernatant 
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Fig. 3 Amylase and Xylanase production by the different strains of S. lividans. a, c Diagram of the expression plasmids pNRoxAnti-Amy and 
pNRoxAnti-Xyl. b, d Amylase (b) and xylanase (d) production by S. lividans wt, S. lividans ΔTA and S. lividans ΔTA-Tox transformed with pNRoxAnti-Amy 
(b) and pNRoxAnti-Xyl (d) after 6 days of culture in YES medium supplemented with 3% xylose. 10 µL of the supernatant was loaded into each track
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of each subculture was analyzed by SDS-PAGE after 
6  days (Fig.  6e, g). Also enzymatic activity was meas-
ured (Fig. 6f, h) and compared with the activity obtained 
in the first culture of the series. It should be noted that 
there was even an enhanced production of both amylase 
and xylanase throughout the different passages, and as 
consequence an increase in the enzymatic activity of the 
supernatants.
All of these results support the robustness and stability 
of this improved selection system.
Conclusions
In this work, a system that is completely free of antibiotic 
resistance genes and useful for the production of high 
yields of proteins in Streptomyces without the use of anti-
biotics as selective agents is reported.
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This system is an improved version of the system previ-
ously described by our group, and is based on the sepa-
ration of the two components of the yefM/yoeBsl (toxin/
antitoxin) operon. The absence of antibiotic resistance 
genes brings additional value to this expression system 
and makes using Streptomyces as a host a powerful tool 
for the production of proteins that can be used within 
different industrial sectors.
Methods
Bacterial strains and growth conditions
The E. coli DH5α strain [38] was used for the cloning and 
isolation of plasmids. It was grown in Luria–Bertani (LB) 
liquid broth or on LB agar. All manipulations in E. coli 
were done following standard procedures [38, 39].
Streptomyces lividans 1326 and derivatives were 
grown on solid R2YE medium for transformation, on 
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track. b, d Amylase (b) and xylanase (d) activity of the supernatants. The histogram bars are the means of three experiments
(See figure on next page.) 
Fig. 6 Enzyme production after strains storage and after serial subcultures. a and c Amylase and xylanase production by S. lividans ΔTA-Tox trans-
formed with pRoxAnti-Amy (a) and pRoxAnti-Xyl (c) after mycelia storage (M) and after sporulation (S). 10 µL of the supernatant collected after 
6 days was loaded into each track. b and d Percentages of amylase (b) and xylanase (d) activity of the supernatants compared with the original 
culture (1). e and g Amylase and xylanase production by S. lividans ΔTA-Tox transformed with pRoxAnti-Amy (e) and pRoxAnti-Xyl (g) after three 
100-fold serial dilutions every 2 days (P1, P2, and P3) in fresh YES medium supplemented with 3% xylose. 10 µL of supernatants collected after 
6 days was loaded into each track. f and h percentage of amylase (f) and xylanase (h) activity of the supernatants. The histogram bars are the mean 
of three experiments
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MSA medium for sporulation [40], and in liquid YES 
medium (1% yeast extract, 10.3% sucrose, 5 mM  MgCl2) 
supplemented with 0.5% glucose and 0.5% glycine for 
collecting cells to make protoplasts, and YES medium 
supplemented with 3% xylose for protein expression. Liq-
uid cultures were carried out in baffled flasks at 28 °C and 
200 rpm. All manipulations in Streptomyces were done as 
indicated by Kieser [40].
Apramycin gene deletion in the host strain
Protoplasts of S. lividans ΔTA-pTES-Tox (pGM160-
YefMslts) [22] were transformed with  pALCrets [33] and 
selected with 100  μg/mL hygromycin. Single colonies 
were reinoculated in patches on R2YE plates with 100 μg/
mL hygromycin for 3  days and then cultured in TSB 
medium with 15 μg/mL thiostrepton for 3 days. Follow-
ing on, serial dilutions of these cultures were streaked 
out to obtain single colonies on YEPD plates with 15 μg/
mL thiostrepton. The single colonies were picked and 
streaked in parallel on YEPD agar and YEPD agar with 
50 μg/mL apramycin to check for the loss of apramycin 
resistance. Elimination of apramycin resistance gene was 
checked by PCR from S. lividans ∆TA-Tox genomic DNA 
using primers LS-113 and LS-114 (Table 1), and the pres-
ence of the toxin (yoeBsl) gene in the genome was con-
firmed by PCR with primers LS008 and LS009 (Table 1).
Neomycin gene deletion in the expression plasmids
Transformation of the host strain with the expression 
plasmids and colony selection was done as described 
in Sevillano et  al. [22]. Protoplasts of S. lividans ∆TA-
Tox (pNRoxAnti-Amy) or ∆TA-Tox (pNRoxAnti-Xyl) 
were transformed with  pALDrets [33] and selected 
with 100  μg/mL hygromycin. Single colonies were rein-
oculated in patches on R2YE plates for 3 days and then 
streaked out on R2YE plates to obtain single colonies. 
The single colonies were picked and streaked in parallel 
on R2YE agar, R2YE agar with 15 μg/mL neomycin and 
R2YE agar with 100 μg/mL hygromycin to check for the 
loss of neomycin resistance and the loss of the  pALDrets 
plasmid. Elimination of the neomycin resistance gene in 
the plasmid was checked by PCR using primers LS-124 
and LS-125 (Table 1) and by restriction analysis.
Plasmid constructions
pTES‑Tox
Plasmid pN702Gem3-Tox [21] was digested with BglII, 
and the DNA fragment containing the yoeBsl (toxin) gene 
was ligated with pTES [33] (Table  2) digested with the 
same enzyme. In this plasmid, the toxin gene is regulated 
by the xysA promoter and is flanked by two transcrip-
tional terminators. Two loxP sites are flanking the toxin 
gene and the phage attachment attP site (Fig. 2).
pN702Gem3Rox
Plasmid pN702Gem3 [37] was digested with BlpI, blunt 
ended with DNA polymerase klenow fragment and 
then digested with NheI. The DNA fragment contain-
ing the aph(3′) (neomycin resistance) gene was ligated 
into pTOS [33] digested with EcoRV and XbaI to obtain 
pTOS-Neo, which was used as an intermediate plasmid. 
To obtain pN702Gem3Rox, pTOS-Neo was digested with 
BspHI and HincII, and the DNA fragment containing the 
aph(3′) gene flanked by rox sites was blunt ended and 
ligated into pN702Gem3 digested with BlpI and NheI and 
blunt. In this plasmid two rox sites flank the neomycin 
resistance gene.
pN702Gem3Rox‑Anti‑T
yefMsl (antitoxin) was amplified by PCR from S. liv-
idans 1326 genomic DNA using primers LS-005 and 
LS-007 (Table  1). The resulting fragment was digested 
with NdeI and HindIII and ligated into plasmid pXHis1, 
[41] (Table 2) digested with the same enzymes, to obtain 
Table 1 Oligonucleotides used
Name Sequence 5′–3′ Use
LS-005 TTTTTTCATATGTCCATCACCGCCAGCGAAG Forward (Fd) for yefMsl amplification. NdeI sequence is underlined
LS-007 TTTTTTAAGCTTCACGCCCGCTCCGCGTCCG Reverse (Rev) for yefMsl amplification. HindIII sequence is underlined
LS-008 TTTTTTCATATGAGGATCACTTTCACGTCCCAC Fd for yoeBsl amplification. NdeI sequence is underlined
LS-009 TTTTTTCTCGAGTCAGTAGTGGTAGCGCGCCTGG Rev for yoeBsl amplification. XhoI sequence is underlined
LS-113 CGACTGATGTCATCAGCGGTGG Fd for aac(3′)IV (apramycin resistance gene) amplification
LS-114 CCAACGTCATCTCGTTCTCCGC Rev for aac(3′)IV (apramycin resistance gene) amplification
LS-124 ATGATTGAACAAGATGGATTGCACG Fd for aph(3′) (neomycin resistance gene) amplification
LS-125 TCAGAAGAACTCGTCAAGAAGGCG Rev for aph(3′) (neomycin resistance gene) amplification
MRG-11 TTTTTTCATATGGCCCGCAGACTCCGCACC Fd for amy amplification. NdeI sequence is underlined
MRG-12 TTTTTTCTCGAGGCCGCGCCAGGTGTCGTTGAG Rev for amy amplification. XhoI sequence is underlined
LS-116 CATATGGCTCAGAATCCCCCGG Fd for xysA amplification
LS-117 CTCGAGCGCGGCGAGCACCG Rev for xysA amplification
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plasmid pXHis1-Anti-T, which was used as an interme-
diate plasmid. Plasmid pN702Gem3Rox-Anti-T was 
obtained by digesting pXHis1-Anti-T with BglII, purify-
ing the corresponding yefMsl band and ligating it into 
pN702Gem3Rox digested with the same enzyme. In this 
plasmid, the antitoxin gene is regulated by the xysA pro-
moter and lacks the fdt transcriptional terminator at 3′ 
end.
pNRoxAnti‑Xyl
This plasmid contains the ORF of the xylanase xysA gene 
from S. halstedii [35] under the control of the S. lividans 
pstS promoter, and the ORF coding for the antitoxin 
(YefMsl) under the control of the xysA promoter. The 
plasmid originated from the pNUF5 plasmid [36] which 
contains the xylanase gene regulated by pstSp; pNUF5 
was digested with BspHI and NheI, and the xysA gene 
band was ligated into pN702Gem3Rox-Anti-T digested 
with BspHI and XbaI.
pNRoxAnti‑Amy
This plasmid contains the ORF of the amylase gene from 
S. griseus [34] under the control of the S. lividans pstS 
promoter and the ORF coding for the antitoxin (YefMsl) 
under the control of the xysA promoter. To construct 
the plasmid, plasmid pNUF-Amy [22], which contains 
the amylase gene regulated by pstSp, was digested with 
BspHI and NheI and the corresponding band was ligated 
into pN702Gem3Rox-Anti-T digested with BspHI and 
XbaI.
Sequence analyses
All constructions were sequenced on both strands using 
a Perkin Elmer ABI Prism 377 DNA sequencer. In silico 
plasmids were obtained with the Gene Construction Kit 
software (GCK, Textco).
Protein analysis
Protein profiles were analysed by denaturing polyacryla-
mide gel electrophoresis (SDS-PAGE) in a MiniProtean 
II system (Bio-Rad). Proteins were detected by 0.5% 
Coomassie brilliant blue R staining and low molecular 
weight standards from Bio-Rad were used as markers.
Xylanase and amylase activities assays
Xylanase activity was measured with the dinitrosalicylic 
acid (DNS) method [42] using xylose as standard. One 
unit of xylanase activity was defined as the amount of 
enzyme required to release 1 µmol of reducing sugars in 
1 min (expressed as xylose equivalents). All data shown 
are means of at least three different experiments.
Amylase activity was measured with the method 
described by Xiao [43]. One unit of amylase activity was 
defined as the amount of enzyme required to degrade 
1 mg of soluble starch in 1 h. All data shown are means of 
at least three different experiments.
Table 2 Plasmids used
Plasmid Characteristics Reference
pGM160 E. coli/Streptomyces shuttle vector. Thiostrepton and gentamicin resistance [44]
pGM160-YefMsl pGM160 derivative. The xysA promoter from S. halstedii controls yefMsl expression [21]
pN702Gem3 E. coli/Streptomyces shuttle vector. Neomycin resistance. High-copy number [37]
pN702Gem3-Tox pN702GEM3 derivative. The xysA promoter from S. halstedii controls toxin expression [21]
pTES E. coli/Streptomyces shuttle vector. Apramycin resistance. Integrative plasmid. attP flanked by loxP sites [33]
pTES-Tox pTES derivative. The xysA promoter from S. halstedii controls toxin expression This work
pXHis1 pBluescript SK derivative. Ampicillin resistance. The xysA promoter from S. halstedii controls xylanase expression [41]
pXHis1-Anti-T pXHis1 derivative. The xysA promoter from S. halstedii controls antitoxin expression This work
pTOS E. coli/Streptomyces shuttle vector. Apramycin resistance. Integrative plasmid. attP flanked by rox sites [33]
pTOS-Neo pTOS derivative. The neomycin resistance gene is flanked by rox sites This work
pN702Gem3Rox pN702Gem3 derivative. The neomycin resistance gene is flanked by rox sites This work
pN702Gem3Rox-Anti-T pN702Gem3Rox derivative. The xysA promoter from S. halstedii controls antitoxin expression This work
pNUF5 pN702Gem3 derivative. The pstS promoter from S. lividans controls xylanase expression [36]
pNUF-Amy pNUF5 derivative. The pstS promoter from S. lividans controls amylase expression [22]
pNRoxAnti-Xyl pN702Gem3Rox-Anti-T derivative. The xysA promoter from S. halstedii controls antitoxin expression and the pstS 
promoter from S. lividans controls xylanase expression
This work
pNRoxAnti-Amy pN702Gem3Rox-Anti-T derivative. The xysA promoter from S. halstedii controls antitoxin expression and the pstS 
promoter from S. lividans controls amylase expression
This work
pRoxAnti-Xyl pNRoxAnti-Xyl derivative without neomycin resistance gene This work
pRoxAnti-Amy pNRoxAnti-Amy derivative without neomycin resistance gene This work
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